Acumen Pharmaceuticals (ABOS) Corporate presentation summary

Market opportunity and unmet need

• Early Alzheimer's disease represents a significant and expanding market, driven by an aging population and improved early diagnosis through blood-based biomarkers.

• Current anti-amyloid therapies are gaining traction, but there is demand for treatments with improved efficacy, safety, and convenience, especially those targeting earlier disease stages.

Pipeline and clinical development

• Sabirnetug (ACU193) is a monoclonal antibody highly selective for toxic amyloid beta oligomers, with positive Phase 1 results and Phase 2 topline data expected in late 2026.

• The ALTITUDE-AD Phase 2 study is fully enrolled (n=542), with topline results anticipated in late 2026 and an open-label extension underway.

• A subcutaneous formulation of sabirnetug has shown favorable pharmacokinetics and safety in healthy volunteers, supporting further development for more convenient dosing.

• The EBD™ (enhanced brain delivery) program aims to develop next-generation antibodies with improved brain penetration, with preclinical candidate data expected in early 2026 and IND filing targeted for mid-2027.

Clinical data and differentiation

• Sabirnetug demonstrated dose-proportional target engagement, significant reductions in amyloid plaque, and improvements in CSF and plasma biomarkers associated with AD pathology after only three doses.

• Safety profile is compelling, with a low incidence of ARIA-E and no cases in ApoE4 homozygotes, differentiating it from other antibodies.

• Comparative biomarker and plaque reduction data suggest sabirnetug matches or exceeds other leading anti-amyloid agents at similar timepoints.